PT  - JOURNAL ARTICLE
AU  - Wood, Mariah S.
AU  - Halmer, Nicole
AU  - Bertolli, Jeanne
AU  - Amsden, Laura B.
AU  - Nugent, Joshua R.
AU  - Lin, Jin-Mann S.
AU  - Rothrock, Gretchen
AU  - Nadle, Joelle
AU  - Chai, Shua J.
AU  - Champsi, Jamila H.
AU  - Yang, James
AU  - Unger, Elizabeth R.
AU  - Skarbinski, Jacek
AU - STOP-ME/CFS and COVID-SELECT
TI  - Underdiagnosis of myalgic encephalomyelitis/chronic fatigue syndrome-like illness in a large integrated healthcare system — Kaiser Permanente Northern California, 2022-2023
AID  - 10.1101/2024.12.04.24318508
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.12.04.24318508
4099  - http://medrxiv.org/content/early/2024/12/06/2024.12.04.24318508.short
4100  - http://medrxiv.org/content/early/2024/12/06/2024.12.04.24318508.full
AB  - Background Surveillance of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a chronic, debilitating multisystem illness, is challenging because ME/CFS can be under-recognized in healthcare settings.Methods Using a population-based panel study of 9,820 adult members of Kaiser Permanente Northern California (KPNC), a large, integrated healthcare system, we compared survey-defined ME/CFS-like illness with presence of an ME/CFS diagnosis in the electronic health record (EHR) to evaluate ME/CFS underdiagnosis.Results Of those with survey-defined ME/CFS-like illness, an estimated 97.8% (95% confidence interval [CI] 97.1%-98.4%) did not have an ME/CFS diagnosis in the EHR. The group without EHR diagnosis was younger, less likely to identify as white non-Hispanic, and more likely to have developed fatigue in the past three years than the EHR diagnosed group. Both diagnosed and undiagnosed ME/CFS-like illness groups had significantly impaired physical, cognitive, and social functioning, and significantly worse mental health and anxiety than those without ME/CFS-like illness.Conclusion ME/CFS is underdiagnosed in the Kaiser Permanente Northern California healthcare system. Enhanced syndromic surveillance that characterizes patients with ME/CFS who have not been diagnosed has the potential to increase timely recognition of ME/CFS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Kaiser Permanente Northern California Institutional Review Board (IRB #1692449). Informed written consent was obtained for all participants in this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll available data is presented in the manuscript, tables, figures and supplementary materials in this manuscript. Sharing of additional de-identified data from this study is restricted by the Health Insurance Portability and Accountability Act of 1996 (HIPAA) as a portion of the data is abstracted from electronic health records as part of routine clinical care.